Posted by Michael Wonder on 16 Jul 2024
Elranatamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments
12 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of elranatamab in the NHS in England.
Elranatamab is recommended with managed access as an option for the treatment of adults with relapsed and refractory multiple myeloma after three or more lines of treatment (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment.
